Abstract
To the Editor .— This February the Committee on Fetus and Newborn of the American Academy of Pediatrics (AAP) and the Fetus and Newborn Committee of the Canadian Paediatric Society (CPS) advised, among other recommendations, that the postnatal use of systemic dexamethasone for the prevention or treatment of chronic lung disease should be limited to randomized, controlled trials with survival without long-term developmental impairments as the major endpoint.1 This past June, Halliday, commenting on the early use of dexamethasone, repeated the statements of the AAP and the CPS, and specifically recommended the DART study.2 The DART study is recruiting infants of either <1000 g birth weight or <28 weeks’ gestation who are ventilator-dependent after …
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
